(SLE)
TEBOTELIMAB(INNC)
IMMUNOGLOBULIN G4-KAPPA, ANTI-[HOMO SAPIENS PDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)] AND ANTI-[HOMO SAPIENS LAG3 (LYMPHOCYTE ACTIVATING 3, LYMPHOCYTE-ACTIVATION 3, CD223)], HUMANIZED MONOCLONAL ANTIBODY, BISPECIFIC TETRAVALENT; GAMMA4 HEAVY CHAIN SCFV-H-CH2-CH3 HUMANIZED (1- 496) [V-KAPPA ANTI-LAG3 (HOMO SAPIENS IGKV1- 39*01 (88.4%) -IGKJ4*01 (90.9%)) [6.3.9] (1-107) -8- MER LINKER (108-115) -VH ANTI-PDCD1 (HOMO SAPIENS IGHV1-46*01 (81.6%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.12] (116-234) -6-MER DIGLYCYL-CYSTEINYL-TRIGLYCYL LINKER (235-240) -E-COIL MOTIF (241-268) -HOMO SAPIENS IGHG4*01, G4V5 H P10, G4V21 CH2 Y15.1, T16, E18 (HINGE 1-12 S10>P (278) (269-280), CH2 M15.1>Y (302), S16>T (304), T18>E (306) (281-390), CH3 (391-495), CHS K>DEL (496) (269-496))], PROPOSED INN: LIST 122(WHO)
TEBOTELIMABUM(INN)